FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Go back to FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 125.31 -2.31 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.62 | 52 Week High | $118.49 | |||
| Open | $127.85 | 52 Week Low | $55.00 | |||
| Day High | $128.72 | P/E | N/A | |||
| Day Low | $125.23 | EPS | $-0.56 | |||
| Volume | 3,700,410 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1152.93 +0.49 (0.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1152.44 | 52 Week High | $88.16 | |||
| Open | $1150.00 | 52 Week Low | $67.88 | |||
| Day High | $1157.60 | P/E | 266.88 | |||
| Day Low | $1140.27 | EPS | $4.32 | |||
| Volume | 4,549,709 | |||||
